Pomolic acid exhibits anticancer potential against a docetaxel‑resistant PC3 prostate cell line

  • Authors:
    • Carollina De Araujo Martins
    • Gleice Da Graça Rocha
    • Cerli Rocha Gattass
    • Christina Maeda Takiya
  • View Affiliations

  • Published online on: April 19, 2019     https://doi.org/10.3892/or.2019.7132
  • Pages: 328-338
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Prostate cancer (PC) is one of the leading causes of cancer‑related death in the male population worldwide. Mortality of PC is dependent on tumor recurrence and its progression to metastatic disease. We examined the effects of pentacyclic triterpene pomolic acid (PA) on docetaxel‑resistant PC3 cells. Cell viability was evaluated using the MTT assay. Apoptosis was evaluated by cell cycle analysis using flow cytometry. The activity of multiple drug resistance (MDR) proteins was determined by the accumulation of specific substrates [mitoxantrone, rhodamine 123 and 5‑carboxyfluorescein diacetate (CFDA)]. The evaluation of epithelial to mesenchymal transition (EMT) proteins was conducted by immunocytochemical assays. It was demonstrated that PC3R cells presents multidrug resistance and EMT phenotype and express active P‑gp/ABCB1 and MRP1/ABCC1. It was shown that PA strongly reduced the viability and induced apoptosis of both PC3 and PC3R cell lines. Moreover, PA bypassed P‑gp/ABCB1, downmodulated MRP1/ABCC1 activities, and partially reverted EMT induced by DTX. Our goal was to evaluate the potential of PA for the development of novel strategies to treat castration‑resistant PC.

References

1 

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI

2 

Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P and de Bono JS: Drug discovery in advanced prostate cancer: Translating biology into therapy. Nat Rev Drug Discov. 15:699–718. 2016. View Article : Google Scholar : PubMed/NCBI

3 

Keyes M, Crook J, Morton G, Vigneault E, Usmani N and Morris WJ: Treatment options for localized prostate cancer. Can Fam Physician. 59:1269–1274. 2013.PubMed/NCBI

4 

Dai C, Heemers H and Sharifi N: Androgen signaling in prostate cancer. Cold Spring Harb Perspect Med. 7(pii): a0304522017. View Article : Google Scholar : PubMed/NCBI

5 

Sumanasuriya S and de Bono J: Treatment of advanced prostate cancer-A review of current therapies and future promise. Cold Spring Harb Perspect Med. 8(pii): a0306352018. View Article : Google Scholar : PubMed/NCBI

6 

Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et al: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 351:1502–2512. 2004. View Article : Google Scholar : PubMed/NCBI

7 

De Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, Gravis G, Bodrogi I, Mackenzie MJ, Shen L, et al: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet. 376:1147–1154. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Seruga B, Ocana A and Tannock IF: Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol. 8:12–23. 2011. View Article : Google Scholar : PubMed/NCBI

9 

Nakazawa M, Paller C and Kyprianou N: Mechanisms of therapeutic resistance in prostate cancer. Curr Oncol Rep. 19:132017. View Article : Google Scholar : PubMed/NCBI

10 

Sridhar SS, Freedland SJ, Gleave ME, Higano C, Mulders P, Parker C, Sartor O and Saad F: Castration-resistant prostate cancer: From new pathophysiology to new treatment. Eur Urol. 65:289–299. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Arsov C, Winter C, Rabenalt R and Albers P: Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel. Urol Oncol. 30:762–771. 2012. View Article : Google Scholar : PubMed/NCBI

12 

Chandrasekar T, Yang JC, Gao AC and Evans CP: Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 4:365–380. 2015.PubMed/NCBI

13 

Gill BS, Kumar S and Navgeet: Triterpenes in cancer: Significance and their influence. Mol Biol Rep. 43:881–896. 2016. View Article : Google Scholar : PubMed/NCBI

14 

Fernandes J, Weinlich R, Castilho RO, Amarante-Mendes GP and Gattass CR: Pomolic acid may overcome multidrug resistance mediated by overexpression of anti-apoptotic Bcl-2 proteins. Cancer Lett. 245:315–320. 2007. View Article : Google Scholar : PubMed/NCBI

15 

Lúcio KA, Rocha Gda G, Monção-Ribeiro LC, Fernandes J, Takiya CM and Gattass CR: Oleanolic acid initiates apoptosis in non-small cell lung cancer cell lines and reduces metastasis of a B16F10 melanoma model in vivo. PLoS One. 6:e285962011. View Article : Google Scholar : PubMed/NCBI

16 

Yan XJ, Gong LH, Zheng FY, Cheng KJ, Chen ZS and Shi Z: Triterpenoids as reversal agents for anticancer drug resistance treatment. Drug Discov Today. 19:482–488. 2014. View Article : Google Scholar : PubMed/NCBI

17 

Fernandes J, Castilho RO, da Costa MR, Wagner-Souza K, Coelho Kaplan MA and Gattass CR: Pentacyclic triterpenes from Chrysobalanaceae species: Cytotoxicity on multidrug resistant and sensitive leukemia cell lines. Cancer Lett. 190:165–169. 2003. View Article : Google Scholar : PubMed/NCBI

18 

Vasconcelos FC, Gattass CR, Rumjanek VM and Maia RC: Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profile. Invest New Drugs. 25:525–533. 2007. View Article : Google Scholar : PubMed/NCBI

19 

Li X, Song Y, Zhang P, Zhu H, Chen L, Xiao Y and Xing Y: Oleanolic acid inhibits cell survival and proliferation of prostatecancer cells in vitro and in vivo through the PI3K/Akt pathway. Tumor Biol. 37:7599–7613. 2016. View Article : Google Scholar

20 

Shin J, Lee HJ, Jung DB, Jung JH, Lee HJ, Lee EO, Lee SG, Shim BS, Choi SH, Ko SG, et al: Suppression of STAT3 and HIF-1 alpha mediates anti-angiogenic activity of betulinic acid in hypoxic PC-3 prostate cancer cells. PLoS One. 6:e214922011. View Article : Google Scholar : PubMed/NCBI

21 

Shanmugam MK, Manu KA, Ong TH, Ramachandran L, Surana R, Bist P, Lim LH, Kumar AP, Hui KM and Sethi G: Inhibition of CXCR4/CXCL12 signaling axis by ursolic acid leads to suppression of metastasis in transgenic adenocarcinoma of mouse prostate model. Int J Cancer. 129:1552–1563. 2011. View Article : Google Scholar : PubMed/NCBI

22 

O'Neill AJ, Prencipe M, Dowling C, Fan Y, Mulrane L, Gallagher WM, O'Connor D, O'Connor R, Devery A, Corcoran C, et al: Characterisation and manipulation of docetaxel resistant prostate cancer cell lines. Mol Cancer. 10:1262011. View Article : Google Scholar : PubMed/NCBI

23 

Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI

24 

Nakazawa M, Paller C and Kyprianou N: Mechanisms of therapeutic resistance in prostate cancer. Curr Oncol Rep. 19:132017. View Article : Google Scholar : PubMed/NCBI

25 

Kojima K, Fujita Y, Nozawa Y, Deguchi T and Ito M: MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate. 70:1501–1512. 2010. View Article : Google Scholar : PubMed/NCBI

26 

Lee BY, Hochgräfe F, Lin HM, Castillo L, Wu J, Raftery MJ, Martin Shreeve S, Horvath LG and Daly RJ: Phosphoproteomic profiling identifies focal adhesion kinase as a mediator of docetaxel resistance in castrate-resistant prostate cancer. Mol Cancer Ther. 13:190–201. 2014. View Article : Google Scholar : PubMed/NCBI

27 

Karatas OF, Guzel E, Duz MB, Ittmann M and Ozen M: The role of ATP-binding cassette transporter genes in the progression of prostate cancer. Prostate. 76:434–444. 2016. View Article : Google Scholar : PubMed/NCBI

28 

Zhu Y, Liu C, Armstrong C, Lou W, Sandher A and Gao AC: Anti-androgens inhibit ABCB1 efflux and ATPase activity and reverse docetaxel resistance in advanced prostate cancer. Clin Cancer Res. 21:4133–4142. 2015. View Article : Google Scholar : PubMed/NCBI

29 

Lombard AP, Liu C, Armstrong CM, Cucchiara V, Gu X, Lou W, Evans CP and Gao AC: ABCB1 mediates cabazitaxel-docetaxel cross-resistance in advanced prostate cancer. Mol Cancer Ther. 16:2257–2266. 2017. View Article : Google Scholar : PubMed/NCBI

30 

Zhu Y, Liu C, Nadiminty N, Lou W, Tummala R, Evans CP and Gao AC: Inhibition of ABCB1 expression overcomes acquired docetaxel resistance in prostate cancer. Mol Cancer Ther. 12:1829–1836. 2013. View Article : Google Scholar : PubMed/NCBI

31 

Sánchez C, Mercado A, Contreras HR, Mendoza P, Cabezas J, Acevedo C, Huidobro C and Castellón EA: Chemotherapy sensitivity recovery of prostate cancer cells by functional inhibition and knock down of multidrug resistance proteins. Prostate. 71:1810–1817. 2011. View Article : Google Scholar : PubMed/NCBI

32 

Zalcberg J, Hu XF, Slater A, Parisot J, El-Osta S, Kantharidis P, Chou ST and Parkin JD: MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis. 3:66–75. 2000. View Article : Google Scholar : PubMed/NCBI

33 

Rocha Gda G, Simões M, Oliveira RR, Kaplan MA and Gattass CR: 3β-acetyl tormentic acid induces apoptosis of resistant leukemia cells independently of P-gp/ABCB1 activity or expression. Invest New Drugs. 30:105–113. 2012. View Article : Google Scholar : PubMed/NCBI

34 

Meng Y, Lin ZM, Ge N, Zhang DL, Huang J and Kong F: Ursolic acid induces apoptosis of prostate cancer cells via the PI3K/Akt/mTOR Pathway. Am J Chin Med. 43:1471–1486. 2015. View Article : Google Scholar : PubMed/NCBI

35 

Yoo KH, Park JH, Lee DK, Fu YY, Baek NI and Chung IS: Pomolic acid induces apoptosis in SK-OV-3 human ovarian adenocarcinoma cells through the mitochondrial-mediated intrinsic and death receptor-induced extrinsic pathways. Oncol Lett. 5:386–390. 2013. View Article : Google Scholar : PubMed/NCBI

36 

Guimarães LPTP, Rocha GDG, Queiroz RM, Martins CA, Takiya CM and Gattass CR: Pomolic acid induces apoptosis and inhibits multidrug resistance protein MRP1 and migration in glioblastoma cells. Oncol Rep. 38:2525–2534. 2017. View Article : Google Scholar : PubMed/NCBI

37 

Tamaki H, Harashima N, Hiraki M, Arichi N, Nishimura N, Shiina H, Naora K and Harada M: Bcl-2 family inhibition sensitizes human prostate cancer cells to docetaxel and promotes unexpected apoptosis under caspase-9 inhibition. Oncotarget. 5:11399–11412. 2014. View Article : Google Scholar : PubMed/NCBI

38 

Park JH, Yoon J and Park B: Pomolic acid suppresses HIF1α/VEGF-mediated angiogenesis bytargeting p38-MAPK and mTOR signaling cascades. Phytomedicine. 23:1716–1726. 2016. View Article : Google Scholar : PubMed/NCBI

39 

McCall P, Bennett L, Ahmad I, Mackenzie LM, Forbes IW, Leung HY, Sansom OJ, Orange C, Seywright M, Underwood MA, et al: NFκB signalling is upregulated in a subset of castrate-resistant prostate cancer patients and correlates with disease progression. Br J Cancer. 107:1554–1563. 2012. View Article : Google Scholar : PubMed/NCBI

40 

Codony-Servat J, Marín-Aguilera M, Visa L, García-Albéniz X, Pineda E, Fernández PL, Filella X, Gascón P and Mellado B: Nuclear factor-kappa B and interleukin-6 related docetaxel resistance in castration-resistant prostate cancer. Prostate. 73:512–521. 2013. View Article : Google Scholar : PubMed/NCBI

41 

Zhang L, Altuwaijri S, Deng F, Chen L, Lal P, Bhanot UK, Korets R, Wenske S, Lilja HG, Chang C, et al: NF-kappaB regulates androgen receptor expression and prostate cancer growth. Am J Pathol. 175:489–499. 2009. View Article : Google Scholar : PubMed/NCBI

42 

Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH and Li Y: PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis. 5:e14372014. View Article : Google Scholar : PubMed/NCBI

43 

Marín-Aguilera M, Codony-Servat J, Reig Ò, Lozano JJ, Fernández PL, Pereira MV, Jiménez N, Donovan M, Puig P, Mengual L, et al: Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer. Mol Cancer Ther. 13:1270–1284. 2014. View Article : Google Scholar : PubMed/NCBI

44 

Puhr M, Hoefer J, Schäfer G, Erb HH, Oh SJ, Klocker H, Heidegger I, Neuwirt H and Culig Z: Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205. Am J Pathol. 181:2188–2201. 2012. View Article : Google Scholar : PubMed/NCBI

45 

Liu K, Guo L, Miao L, Bao W, Yang J, Li X, Xi T and Zhao W: Ursolic acid inhibits epithelial-mesenchymal transition by suppressing the expression of astrocyte-elevated gene-1 in human nonsmall cell lung cancer A549 cells. Anticancer Drugs. 24:494–503. 2013. View Article : Google Scholar : PubMed/NCBI

46 

Sohn EJ, Won G, Lee J, Yoon SW, Lee I, Kim HJ and Kim SH: Blockage of epithelial to mesenchymal transition and upregulation of let 7b are critically involved in ursolic acid induced apoptosis in malignant mesothelioma cell. Int J Biol Sci. 12:1279–1288. 2016. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

July 2019
Volume 42 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Martins, C., Rocha, G., Gattass, C., & Takiya, C. (2019). Pomolic acid exhibits anticancer potential against a docetaxel‑resistant PC3 prostate cell line . Oncology Reports, 42, 328-338. https://doi.org/10.3892/or.2019.7132
MLA
Martins, C., Rocha, G., Gattass, C., Takiya, C."Pomolic acid exhibits anticancer potential against a docetaxel‑resistant PC3 prostate cell line ". Oncology Reports 42.1 (2019): 328-338.
Chicago
Martins, C., Rocha, G., Gattass, C., Takiya, C."Pomolic acid exhibits anticancer potential against a docetaxel‑resistant PC3 prostate cell line ". Oncology Reports 42, no. 1 (2019): 328-338. https://doi.org/10.3892/or.2019.7132